5 Best Economic Recovery Stocks to Buy

3. Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Number of Hedge Funds In Q1 2023: 57

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a biotechnology company that develops a variety of treatments for diseases such as muscular dystrophy and genetic mutations. Its average share price target has a $65 upside, and the average rating is Strong Buy.

As of March 2023, 57 of the 943 hedge funds part of Insider Monkey’s database had invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Kurt Von Emster’s VenBio Select Advisor is the largest investor with a $503 million stake.

Follow Sarepta Therapeutics Inc. (NASDAQ:SRPT)